Publikasi Scopus 926 artikel (Per 14 Maret 2022)

Li S., Tarlac V., Christanto R.B.I., French S.L., Hamilton J.R.
57211771149;6505711498;57218589212;56115043700;7403703575;
Determination of PAR4 numbers on the surface of human platelets: no effect of the single nucleotide polymorphism rs773902
2021
Platelets
32
7
988
991
Australian Centre for Blood Diseases, Monash University, Melbourne, Australia; Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
Li, S., Australian Centre for Blood Diseases, Monash University, Melbourne, Australia; Tarlac, V., Australian Centre for Blood Diseases, Monash University, Melbourne, Australia; Christanto, R.B.I., Australian Centre for Blood Diseases, Monash University, Melbourne, Australia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; French, S.L., Australian Centre for Blood Diseases, Monash University, Melbourne, Australia; Hamilton, J.R., Australian Centre for Blood Diseases, Monash University, Melbourne, Australia
The thrombin receptor, protease-activated receptor 4 (PAR4), is important for platelet activation and is the target of emerging anti-thrombotic drugs. A frequently occurring single nucleotide polymorphism (SNP; rs773902) causes a function-altering PAR4 sequence variant (NC_000019.10:p.Ala120Thr), whereby platelets from Thr120-expressing individuals are hyper-responsive to PAR4 agonists and hypo-responsive to some PAR4 antagonists than platelets from Ala120-expressing individuals. This altered pharmacology may impact PAR4 inhibitor development, yet the underlying mechanism(s) remain unknown. We tested whether PAR4 surface expression contributes to the altered receptor function. Quantitative flow cytometry was used to determine the absolute number of PAR4 on platelets from individuals subsequently genotyped at rs773902. We detected 539 ± 311 PAR4 per platelet (mean ± SD, n = 84). This number was not different across rs773902 genotypes. This first determination of cellular PAR4 numbers indicates variations in platelet surface expression do not explain the altered pharmacology of the rs773902 PAR4 sequence variant. © 2020 Taylor & Francis Group, LLC.
Platelets; protease-activated receptors; thrombin
proteinase activated receptor 4; protease-activated receptor 4; thrombin receptor; adult; Article; cell surface; controlled study; flow cytometry; genetic association; genotype; human; human cell; protein expression; quantitative analysis; sequence analysis; single nucleotide polymorphism; thrombocyte activation; thrombocyte membrane; blood; metabolism; single nucleotide polymorphism; thrombocyte; Blood Platelets; Humans; Polymorphism, Single Nucleotide; Receptors, Thrombin
Taylor and Francis Ltd.
09537104
32819173
Article
Q2
939
4803